We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
(+3.4%)
Cap. Flow
-$205M
Cap. Flow
% of AUM
-5.76%
Top 10 Holdings %
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31
Avg Time Held Equity + Options
8.4
quarters
Top 10 Avg Time Held Equity + Options
5.8
quarters
Top 20 Avg Time Held Equity + Options
6.1
quarters
Avg Time Held Equity only
8.6
quarters
Top 10 Avg Time Held Equity only
5.8
quarters
Top 20 Avg Time Held Equity only
6.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$79.7M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$45.9M |
| 3 |
Vaxcyte
PCVX
|
+$45.9M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$39.2M |
| 5 |
Acrivon Therapeutics
ACRV
|
+$38.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$158M |
| 2 |
Relmada Therapeutics
RLMD
|
+$88.2M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$43.3M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$38.4M |
| 5 |
Edwards Lifesciences
EW
|
+$27.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.34% |
| 2 | Miscellaneous | 2.57% |
| 3 | Financials | 0.08% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Amicus Therapeutics
FOLD
| $338M | 9.48% |
27,642,917
+270,000
| +1% | +$3.04M |
2014 Q1
35 quarters
|
|
2
Amylyx Pharmaceuticals
AMLX
$3.45B
| $225M | 6.32% |
6,088,333
+616,300
| +11% | +$21.9M |
2022 Q1
3 quarters
|
|
|
3
Madrigal Pharmaceuticals
MDGL
$10.8B
| $212M | 5.97% |
731,932
+400,909
| +121% | +$39.2M |
2021 Q4
4 quarters
|
|
4
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $205M | 5.77% |
6,511,727
| – | – |
2020 Q4
8 quarters
|
|
|
RXDX
5
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $133M | 3.75% |
1,212,694
-255,818
| -17% | -$16.6M |
2021 Q1
7 quarters
|
|
|
VRNA
6
DELISTED
Verona Pharma
VRNA
| $128M | 3.58% |
4,880,719
-166,545
| -3% | -$2.22M |
2020 Q3
9 quarters
|
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $109M | 3.07% |
+960,000
| New | +$79.7M |
2022 Q4
0 quarters
|
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $99.3M | 2.79% |
2,191,425
-593,371
| -21% | -$38.4M |
2018 Q4
16 quarters
|
|
|
LIAN
9
DELISTED
LianBio American Depositary Shares
LIAN
| $94.4M | 2.65% |
57,558,451
| – | – |
2021 Q4
4 quarters
|
|
|
10
PUT
Madrigal Pharmaceuticals
MDGL
$10.8B
| $87.1M | 2.45% |
+300,000
| New | +$29.3M |
2022 Q4
0 quarters
|
|
|
11
Sarepta Therapeutics
SRPT
$1.84B
| $84.1M | 2.36% |
649,250
+396,250
| +157% | +$45.9M |
2022 Q3
1 quarter
|
|
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $81.7M | 2.29% |
3,313,783
+425,923
| +15% | +$12.5M |
2021 Q2
6 quarters
|
|
13
DELISTED
Arcellx
ACLX
| $80.5M | 2.26% |
2,598,305
+132,900
| +5% | +$3.05M |
2022 Q2
2 quarters
|
|
14
Aldeyra Therapeutics
ALDX
$54.6M
| $79M | 2.22% |
11,350,085
| – | – |
2015 Q1
31 quarters
|
|
15
Xenon Pharmaceuticals
XENE
$3.47B
| $75.8M | 2.13% |
1,921,273
-201,262
| -9% | -$7.33M |
2021 Q1
7 quarters
|
|
16
DELISTED
Crinetics Pharmaceuticals
CRNX
| $73.9M | 2.08% |
4,039,276
-1,281,756
| -24% | -$22.6M |
2018 Q3
17 quarters
|
|
|
BLU
17
DELISTED
BELLUS Health Inc.
BLU
| $73.1M | 2.05% |
8,891,027
-1,356,046
| -13% | -$12.6M |
2021 Q4
4 quarters
|
|
18
DELISTED
SpringWorks Therapeutics
SWTX
| $68.1M | 1.91% |
2,617,691
-852,872
| -25% | -$21M |
2019 Q3
13 quarters
|
|
19
DELISTED
Nuvalent
NUVL
| $67.2M | 1.89% |
2,255,007
+600,000
| +36% | +$16.7M |
2021 Q3
5 quarters
|
|
20
Iovance Biotherapeutics
IOVA
$6.6B
| $63.7M | 1.79% |
9,971,780
-276,844
| -3% | -$2.16M |
2015 Q1
31 quarters
|
|
|
21
Vaxcyte
PCVX
$11B
| $56.1M | 1.58% |
+1,170,000
| New | +$45.9M |
2022 Q4
0 quarters
|
|
22
BioMarin Pharmaceuticals
BMRN
$10.7B
| $52.4M | 1.47% |
506,481
+170,000
| +51% | +$16M |
2022 Q2
2 quarters
|
|
23
ADMA Biologics
ADMA
$2.28B
| $46.2M | 1.3% |
11,900,255
+966,868
| +9% | +$2.98M |
2016 Q3
25 quarters
|
|
24
MeiraGTx Holdings
MGTX
$997M
| $45.4M | 1.27% |
6,963,277
| – | – |
2018 Q2
18 quarters
|
|
25
Treace Medical Concepts
TMCI
$267M
| $44.7M | 1.26% |
1,946,403
+344,424
| +21% | +$7.93M |
2021 Q2
6 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q4 2022 Portfolio in Review
As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $205M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.
- Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
- Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
- Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
- Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
- Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
- Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.
Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.